ECR 2023Explore our innovations and step into the future, togetherMarch 1st to 5thVienna (Wien)

ECR 2023
Explore our innovations and step into the future, together

March 1st to 5th
Vienna (Wien)

Contact us

David Hale, CEO of Guerbet and Prof.Dr. Adrian Brady, ESR President warmly welcome you all to the #ECR2023 edition! Check out their conversation below ⬇️

C1 Optiprotect (8)

Join our Symposium: Innovations in Radiology and eco-responsibility: where do we stand?

📅 4th March ⏰ 12:30 PM CET
📌 Room: D, Level -2, AVC 

Chairman - Pr. Carlo Quattrocchi  (Italy)

  • Appropriateness of contrast-enhanced imaging in MRI and CT: a look at current RADS scoring systems. Pr. Carlo Quattrocchi  (Italy)
  • Could MR Innovation lead to a lower Gd footprint? Pr. Majda Thurnher (Austria)
  • Could X-RAY Innovation lead to Contrast Media Change of Practice? Pr. Philippe Douek (France)
IMG 0764RR Optistarelite New

New version of Optistar™Elite,                The next level precision injection in MRI.

OptiStar™ Elite is a dual head MRI contrast delivery system that enables more precise protocols and is configured for the next generation GBCA from Guerbet**.

Microsoftteams Image (37)

Come meet us at our booth #222, Hall X2

Guerbet will exhibit its current range of contrast media, injections systems, medical devices, digital and AI solutions.

 

Guerbet 772X579

#WeReduceDose*

Committed to improving patient care, Guerbet is working with CT & MRI professionals to pave the way for a new era of radiology.

Come and visit us on the ECR Guerbet booth to join the discussion.

* Courtesy of Chelsea Westminster Hospital NHS Foundation Trust. Courtesy of Colin Monaghan, CT Superintendent, Liverpool Heart & Chest Hospital NHS Foundation Trust. Courtesy of Chest & Westminster Hospital NHS Foundation Trust. Courtesy of Colin Monaghan, CT Superintendent, Liverpool Heart & Chest Hospital NHS Foundation Trust. 

Products & Solutions Highlights

Banner Def

Iodine dose reduction

OptiVantage™ Multi-use dual-head CT injector allows a uniform vascular enhancement throughout the procedure. It helps reduce the contrast load up to 40%1, maintain image quality2, all in a 1 click contrast media injection efficiency add-on.

 

Microsoftteams Image (35)

Contrast-Enhanced Mammography

New indication: contrast-enhanced mammography to support the diagnosis of breast cancer

45340 Site Optistar GUERBET Header[33]

New version of OptiStar™ Elite

OptiStar™Elite is a dual head MRI contrast delivery system that enables more precise protocols and is configured for the next generation GBCA from Guerbet**.

Research & Innovation AT YOUR SIDE

Augmented Intelligence

Exchange with our experts on our various AI projects in oncological imaging: prostate, liver, pancreas and bone lesions.

Also, discover with icobrain how you can enhance your clinical routine for neurological conditions.

17

Digital Solutions

Contrast&Care® simplify your contrast media traceability and support informed decisions.

Dose&Care® is a state-of-the-art digital solution to aid monitoring of patient radiation exposure.

 

ECR23 LP Research Pres 772X579px

Discover our research presentations (posters)

  • Different N-(2,3-dihydroxypropyl) carbamoyl side chain: an alternative for iodinated contrast medium-related adverse drug reactions by Pr. Choong Wook Lee (Korea)
  • A review of FDA pharmacovigilance database to assess the importance of symptoms associated with gadolinium exposure (SAGE) by Dr. I. Shahid (UK)
  • 2 more research presentations on GBCAs by Pr. V. Vilgrain (France) and Pr. C. Kuhl (Germany)

References

* Courtesy of Chelsea Westminster Hospital NHS Foundation Trust. Courtesy of Colin Monaghan, CT Superintendent, Liverpool Heart & Chest Hospital NHS Foundation Trust. Courtesy of Chest & Westminster Hospital NHS Foundation Trust. Courtesy of Colin Monaghan, CT Superintendent, Liverpool Heart & Chest Hospital NHS Foundation Trust.

**Data on file; D12582 A; D12766 Rev A; D11839 Rev A. Next generation GBCA from Guerbet being under evaluation by European Health Authorities (EMA) and for use only in countries with applicable health authority registrations. FDA approved.

1. Clinical Cases mentioned in the document:
1st Case: Courtesy of Chelsea Westminster Hospital NHS Foundation Trust
2nd case: Courtesy of Colin Monaghan, CT Superintendent, Liverpool Heart & Chest Hospital NHS Foundation Trust
3rd case: Courtesy of Chest & Westminster Hospital NHS Foundation Trust
4th case: Courtesy of Colin Monaghan, CT Superintendent, Liverpool Heart & Chest Hospital NHS Foundation Trust
2. Internal data: Cattini G.H and Walsh A. - A bolus shaping software used to reduce the amount of contrast given to patients during CT exams without reducing the diagnostic confidence (2010)
Navin, P, Murray, A.M, Nandikumar, K, Waldron, R, Tuohy, B., Shaped-bolus protocol reduces contrast medium volume in abdominal CT while maintaining image quality - Clinical Radiology (Oct 2016)

E23001920